Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer, metastatic

213MO - Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)


10 Sep 2022


Mini Oral session: Breast cancer, metastatic


Tumour Site

Breast Cancer


Monica Arnedos


Annals of Oncology (2022) 33 (suppl_7): S88-S121. 10.1016/annonc/annonc1040


M. Arnedos1, A. Goncalves2, M. Pulido3, F. Lerebours4, O. Tredan5, F. Dalenc6, S. Guiu7, D. Mollon Grange8, L. Teixeira9, C. Levy10, B. Verret11, H.A.S. Dawood12, P. Augereau13, L. Deiana14, S. Ladoire15, E. Carola16, M.A. Mouret Reynier17, C. Guyonneau18, G. MacGrogan19, H. Bonnefoi20

Author affiliations

  • 1 Medical Oncology Dept., Institute Bergonié, 33000 - Bordeaux/FR
  • 2 Medical Oncology Dept., Institute Paoli Calmettes, 13274 - Marseille/FR
  • 3 Biostatistics, Institut Bergonie, 33000 - BORDEAUX/FR
  • 4 Medical Oncology Dept., Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 5 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 6 Medical Oncology Dept., Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 7 34, ICM - Institut du Cancer de Montpellier, 34298 - Montpellier, Cedex /FR
  • 8 Medical Oncology Dept., Centre Hospitalier de Cornouaille - Site de Laennec, 29107 - Quimper, Cedex/FR
  • 9 Breast Disease Unit, Hopital Saint Louis AP-HP, 75010 - Paris/FR
  • 10 Medical Oncology Dept., Centre Francois Baclesse, 14076 - Caen/FR
  • 11 Medical Oncology Dept., Gustave Roussy, 94805 - VILLEJUIF/FR
  • 12 Medical Oncology Department, CHR Orléans, 45067 - Orléans/FR
  • 13 Medical Oncology Department, Centre Paul Papin, 49055 - Angers/FR
  • 14 Medical Oncology Dept., CHRU Brest - Hopital Augustin Morvan, 29200 - Brest/FR
  • 15 Oncology Dept., Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 16 Medical Oncology Dept., GHPSO, 60100 - Creil/FR
  • 17 Medical Oncology Dept., Jean Perrin Center, 63011 - Clermont-Ferrand/FR
  • 18 R&d Department, Unicancer, 75015 - Paris/FR
  • 19 Biology, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), 33000 - Bordeaux/FR
  • 20 Medical Oncology Department, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), 33000 - Bordeaux/FR


Login to access the resources on OncologyPRO.

Abstract 213MO


A subgroup of triple negative breast cancer (TNBC) expresses the androgen receptor (AR). In this trial we evaluated the efficacy and tolerability of the AR inhibitor darolutamide (D) or capecitabine (C) in patients (pts) with advanced AR-positive TNBC (NCT03383679).


Pts with centrally reviewed AR-positive (≥ 10% by immunohistochemistry) TNBC treated with up to one line of chemotherapy for advanced disease were eligible. They were randomized in a 2:1 ratio to receive D 600 mg twice daily or C 1000 mg/m2 twice daily 2-weeks on/ 1-week off, until progression or unacceptable toxicity. Primary endpoint was clinical benefit rate (CBR) at 16 weeks and was assessed in the eligible population and in the sensitivity analysis population (pts with delayed tumour assessment performed in the context of COVID pandemic). Main secondary endpoints included objective response rate, overall survival, progression-free survival (PFS) and safety.


A total of 254 pts from 45 centres were screened; 94 pts were randomized (61 in D arm, 33 in C arm) from April 2018 to July 2021. A clinical benefit was observed in D arm in 13 of 53 evaluable pts (CBR at 16 weeks 24.5%; 95% CI: 12.9%-36.1%) including 2 PR and 1 CR and in C arm in 11 of 23 evaluable pts (CBR at 16 weeks 47.8%; 95% CI: 27.4%-68.2%). In the sensitivity analysis, a clinical benefit was observed in D arm in 17 of 58 evaluable patients (CBR ≥ 16 weeks 29.3%; 95% CI: 17.6%-41.0%) and in C arm in 19 of 32 evaluable patients (CBR ≥ 16 weeks 59.4%; 95% CI: 42.3%-76.4%). 7 pts presented with drug-related serious adverse events: 3 in D arm and 4 in C arm. In D arm, asthenia (26.7%), nausea (25%) and ASAT increase (21.7%) were the most common adverse events, the majority being grade 1 or 2, similar to previous safety data. Median PFS were 1.8 months (CI 95% 1.7-3.1) and 3.6 months (1.8-9.1) in D arm and C arm respectively. Other secondary endpoints will be presented at the meeting.


Despite not reaching the pre-specified CBR, darulotamide demonstrated clinical activity with significant benefit for a group of patients. A research program to identify predictive biomarkers of sensitivity is ongoing.

Clinical trial identification

EudraCT: 2017-002284-18 NCT03383679.

Editorial acknowledgement

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.